In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
|Articles|July 1, 1999
Oncology NEWS International
- Oncology NEWS International Vol 8 No 7
- Volume 8
- Issue 7
Patient Prostate Cancer Guidelines Available
NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.
Advertisement
NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.
Incorporating the clinical experience of the 17 NCCN member institutions, these guidelines offer prostate cancer patients and their families the reliable, specific, and easy-to-understand information they need to make treatment decisions.
In March, the NCCN and ACS released breast cancer guidelines for patients, resulting in 1.5 million visits to the NCCN website.The prostate cancer guidelines are available on the NCCN website (
The prostate cancer treatment guidelines for patients will also be published in the August/September 1999 issue of InTouch, PRR, Inc.s cancer magazine for consumers.
Articles in this issue
over 27 years ago
Nasal Angiogenesis Inhibitor May Stop Kaposi’s Sarcomaover 27 years ago
Surgeon’s Perspective on Neoadjuvant Chemo for Breast Cancerover 27 years ago
STAR Breast Cancer Prevention Trial Begins Enrollmentover 27 years ago
Studies Suggest New Approaches in Hereditary Ovarian Cancerover 27 years ago
Lycopene Beneficial in Prostate Cancerover 27 years ago
Komen Launches REMEMBERover 27 years ago
Advice and Support for Daughters of Breast Cancer Patientsover 27 years ago
Fetus May Be Harmed by Second-Hand Smokeover 27 years ago
Genes Linked to Smoking Affinity, Smoking-Induced Lung Cancerover 27 years ago
Ultraviolet Light Slated for Review as CarcinogenAdvertisement
Related to this article
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
3
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5